Longitudinal changes in kidney parenchymal volume associated with renal artery stenting  by Modrall, J. Gregory et al.
From the Peripheral Vascular Surgery Society
Longitudinal changes in kidney parenchymal
volume associated with renal artery stenting
J. Gregory Modrall, MD,a,b Carlos H. Timaran, MD,a,b Eric B. Rosero, MD,a,b Jayer Chung, MD,b
Mitchell Plummer, MD,b R. James Valentine, MD,b and Clayton Trimmer, DO,c Dallas, Tex
Objective: This study assessed the longitudinal changes in renal volume after renal artery stenting (RAS) to determine if
renal mass is preserved by stenting.
Methods: The study cohort consisted of 38 patients with longitudinal imaging available for renal volume quantification
before and after RAS. Renal volume was estimated as (kidney length) (width) (depth/2) based on preoperative renal
imaging. For each patient, the clinical response of blood pressure (BP) and renal function to RAS was categorized
according to modified American Heart Association guidelines. Changes in renal volume were assessed using paired
nonparametric analyses.
Results: The cohort was a median age of 69 years (interquartile range [IQR], 60-74 years). A favorable BP response was
observed in 11 of 38 patients (28.9%). At a median interval between imaging studies of 21months (IQR, 13-32months),
ipsilateral renal volume was significantly increased from baseline (146.8 vs 133.8 cm3;P  .02). This represents a 6.9%
relative increase in ipsilateral kidney volume from baseline. A significant negative correlation between preoperative renal
volume and the relative change in renal volume postoperatively (r  0.42; P  .0055) suggests that smaller kidneys
experienced the greatest gains in renal volume after stenting. It is noteworthy that the 25 patients with no change in BP
or renal function—clinical failures using traditional definitions—experienced a 12% relative increase in ipsilateral renal
volume after RAS. Multivariate analysis determined that stable or improved renal volume after stenting was an
independent predictor of stable or improved long-term renal function (odds ratio, 0.008; 95% confidence interval,
0.000-0.206; P  .004).
Conclusions: These data lend credence to the belief that RAS preserves renal mass in some patients. This benefit of RAS
even extends to those patients who would be considered treatment failures by traditional definitions. Patients with stable
or increased renal volume after RAS had more stable renal function during long-term follow-up, whereas patients with
renal volume loss after stenting were prone to deterioration of renal function. (J Vasc Surg 2012;55:774-80.)
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lThe treatment of renal artery (RA) occlusive disease
(RAOD) with RA stenting (RAS) is typically aimed at
improving blood pressure (BP) control or salvaging renal
function. Recent studies have documented BP or renal
function improvement in 34% to 80% of patients after RAS,
while others derive no clear benefit.1-7 A key determinant
of the response to RAS may be the condition of the kidney
downstream of an RA stenosis. Chronic renal ischemia due
to RAOD may induce nephrosclerosis, leading to renal
cortical thinning, parenchymal atrophy, and progressive
loss of kidney mass. The clinical consequence of unabated
nephrosclerosis is progressive hypertension or renal insuffi-
ciency that is poorly responsive to renal revascularization.
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774The extent to which renal parenchymal changes in-
uced by RAOD may be reversed by RAS is poorly under-
tood. Some proponents of RAS contend that stenting will
revent further ischemic injury to the kidney and preserve
enal mass, even if there is no improvement in BP or renal
unction. Currently there are limited data to support that
otion. The purpose of this study was to assess the longi-
udinal changes in renal volume after RAS to determine
hether stenting preserves renal mass.
ETHODS
This study was approved by the Institutional Review
oards of the University of Texas Southwestern Medical
chool and the Dallas Veterans Affairs Medical Center.
Study cohort. This retrospective study examined the
utcomes for a cohort of 38 patients who underwent
rimary RAS at the University of Texas SouthwesternMed-
cal School and its affiliated hospitals between January 2000
nd July 2008. The principal inclusion criterion was the
vailability of longitudinal renal imaging with contrast-
nhanced computed tomography (CT) or magnetic reso-
ance (MR) scans for quantification of renal volume before
nd after RAS. Exclusion criteria included nonatheroscle-
otic RA lesions, secondary RA lesions due to restenosis
fter previous angioplasty or stenting, inadequate clinical
ollow-up to assess the clinical outcome of RAS, or a lack of
ongitudinal imaging sufficient to quantify renal volume.
he primary indication for RAS was treatment of hyperten-
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Volume 55, Number 3 Modrall et al 775sion in 21 of the 38 patients (55.3%) and renal insufficiency
in 17 (44.7%).
Clinical data collection. Demographic, clinical, ana-
tomic, and procedural data pertinent to RAS were collected
for each patient. BP control was assessed by calculating an
average resting BP (measured while seated) and the average
number of antihypertensive medications from two to three
clinic visits before stenting and at the last follow-up after
stenting, as described previously.6 All medications with a
potential for influencing BP were included in the tally of
antihypertensive medications, including diuretics and ni-
trates, even if those medications were prescribed for cardiac
indications.
Renal function was characterized by serum creatinine
(mg/dL), estimated glomerular filtration rate (eGFR), and
the proportion of patients requiring renal replacement
therapy. Average preoperative and postoperative serum cre-
atinine and eGFR were calculated from two to three clinic
visits. The abbreviated Modification of Diet in Renal Dis-
ease formula was used to calculate eGFR: 186  (serum
creatinine)1.154  (age)0.203  (0.742 if female) 
(1.210 if African American).8 Patients requiring renal re-
placement therapy were designated as having an eGFR of
10 mL/min/1.73 m2.
Definition of clinical response to RAS. Patients were
categorized as BP and renal function “responders” or “non-
responders” by a modification of AmericanHeart Association
reporting guidelines,9 as reported previously.6,7 The BP re-
sponse to RAS was assessed by comparing the average post-
stenting BP and number of antihypertensive medications at
last follow-up with the average prestenting BP and number of
antihypertensive medications for each patient. “BP respond-
ers” were defined by an average postoperative BP of
160/90 mmHg on a reduced number of antihypertensive
medications or a reduction in average diastolic BP to90mm
Hg on the same number of medications after RAS. All other
patients were categorized as “BP nonresponders.”
The renal function response to RAS was defined in accor-
dance with American Heart Association guidelines,9 which
have been used in prior studies.1,2,5,7 “Renal function re-
sponders” were defined by an improvement in the average
poststenting eGFR at the last follow-up of 20%, compared
with the average prestenting eGFR. Patients with stable renal
function (20% change in eGFR) or worsened renal function
(20% decrease in eGFR) after RAS were analyzed in aggre-
gate as “renal function nonresponders.”
Renal volume determination. Contrast-enhanced
CT or MR scans were used to measure kidney pole-to-pole
length, medial-to-lateral width, and anterior-to-posterior
depth. All measurements were performed in duplicate by an
unblinded reader (J.G.M.) and averaged. From these aver-
age measurements, the estimated kidney volume was calcu-
lated: (kidney length)  (width)  (depth/2). This tech-
nique for assessing kidney volume was previously validated
in an autopsy study10 and used in prior studies.6,11 In-
creased kidney volume was defined as an increase of 5%
over baseline, whereas decreased kidney volume required a
decline in kidney volume by 5%. Stable kidney volume pas defined by any change in kidney volume of 5% over
aseline. When correlating longitudinal changes in kidney
olume with changes in eGFR over time, the two kidney
olumes were averaged for patients with bilateral stenting
o yield a net change in kidney volume.
Statistical analysis. The primary end point of the study
as kidney volume after stenting. Secondary end points in-
luded procedural complications, BP renal function response
o stenting, and survival. Categoric data were reported as
roportions and comparedusing2, Fisher exact, orCochran-
rmitage trend tests. Continuous data were reported as me-
ianswith interquartile ranges (IQRs) and compared between
roups with Mann-WhitneyU, Wilcoxon matched pairs, and
ruskal-Wallis tests, as appropriate. Stepwise multivariate lo-
istic regression analysis was performed to identify indepen-
ent predictors of stable (or improved) long-term renal func-
ion after RAS. Variables that were significant (P  .05) on
nivariate analysis were incorporated into the regression
odel. Survival was calculated according to the Kaplan-Meier
echnique. Survival curves were compared using the log-rank
est. The threshold for significance was .05. Statistical analysis
as performed using SAS 9.13 software (SAS Institute Inc,
ary, NC).
ESULTS
Cohort characteristics before stenting. The baseline
emographics and comorbid conditions for the cohort are
eported in Table I. The age and comorbidities shared by
he cohort typify a patient population with RAOD. Before
tenting, the median systolic BP was 154 mm Hg (IQR,
36-171 mmHg) and median diastolic BP was 76 mmHg
IQR, 66-90 mm Hg). Patients were taking a median of
hree preoperative antihypertensive medications (IQR, 3-4
edications). The median preoperative serum creatinine
as 1.45 mg/dL (IQR, 1.00-1.73 mg/dL). In 17 of 38
atients (44.7%), baseline serum creatinine was 1.5 mg/
L. No patients required renal replacement therapy before
AS. The median eGFR before stenting for the cohort was
1 mL/min/1.73 m2 (IQR, 42-60 mL/min/1.73 m2).
Procedural details. Forty-five RAs were treated in 38
able I. Baseline cohort characteristics (n  38)
isk factor Median (IQR) or No. (%)
ge, years 69 (60-74)
ale gender 21 (55.3)
ace
White 24 (63.2)
African American 11 (28.9)
Hispanic/other 3 (7.9)
ypertension 38 (100)
iabetes 18 (47.4)
oronary artery disease 20 (52.6)
yperlipidemia 17 (44.7)
obacco history 36 (94.7)
hronic obstructive pulmonary
disease
6 (15.7)
QR, Interquartile range.atients, representing 7 bilateral (18.4%) and 31 unilateral
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March 2012776 Modrall et al(71.6%) stenting procedures. Only 2 of the 45 stented RAs
involved solitary kidneys. The median degree of stenosis of
the stented RAs was 75% (IQR, 70%-80%). All stents used
to treat these stenoses were balloon-expandable stents with
a median stent diameter of 6 mm (IQR, 5-6 mm) and
length of 18 mm (IQR, 15-18mm). Predilatation was used
before stenting in 3 of 38 patients (7.9%). Embolic protec-
tion was used in one patient (2.6%).
No immediate complications were noted. Two late
restenoses were documented on follow-up surveillance at 7
and 25 months after stenting. In both cases, the early and
late BP and renal function responses to RAS were congru-
ent, suggesting that the restenosis had no effect on the
clinical outcome for stenting in these patients.
Cohort outcomes. For the cohort at large, the me-
dian duration of follow-up at which both clinical data and
imaging were available was 21 months (IQR, 13-32
months). To assess renal function at later times, eGFR was
assessed at a median of 63 months after stenting (IQR,
33-98 months) in the absence of concurrent imaging. The
outcomes for the cohort are summarized in Table II. RAS
significantly improved systolic and diastolic BP, but stent-
ing did not decrease the number of antihypertensive med-
ications required for BP control. Renal function was not
significantly altered by RAS, based on a comparison of
serum creatinine, eGFR, and proportion of patients who
required hemodialysis before and after stenting.
Patient-specific clinical outcomes. Of the 38 pa-
tients, 11 (28.9%) were categorized as BP responders by the
definition outlined in the Methods section. Responders
experienced a much greater improvement in systolic BP
than nonresponders (32 [IQR, 64 to 14] vs 8 [IQR,
–35 to 9] mm Hg), although this difference was not
statistically significant (P  .14). Diastolic BP was also
improved to a greater extent in responders than in nonre-
sponders (–19 [IQR, –31 to1] vs 0 [IQR, –14 to 8] mm
Hg; P  .03). In addition to lower systolic and diastolic
BPs, significantly fewer antihypertensive medications were
required for responders compared with nonresponders (–1
[IQR, –2 to 0] medication vs no change [IQR, 0-1] in
medication; P  .0001).
Three patients (7.9%) were renal function responders
based on an improvement in eGFR poststenting of 20%
Table II. Cohort outcomes (n  38) after renal artery ste
Variablea Pre-RAS
Blood pressure, mm Hg
Systolic 154 (136-171
Diastolic 76 (66-90)
Antihypertensive agents, No. 3 (3-4)
Serum creatinine,b mg/dL 1.45 (1.00-1.7
eGFR, mL/min/1.73 m2 51 (42-60)
Proportion on dialysis, % 0
eGFR, Estimated glomerular filtration rate.
aCohort data are analyzed in aggregate. Data are presented as medians (inter
bExcluding patients receiving renal replacement therapy.over baseline. The median change in eGFR among these whree patients was 54 mL/min/1.73 m2 (IQR, 28-119
L/min/1.73 m2), whereas the median change in eGFR
mong renal function nonresponders was nil (IQR, –23 to
mL/min/1.73 m2).
Kidney morphometrics and renal volume. Baseline
nd poststenting measurements of kidney pole-to-pole
ength, anterior-to-posterior depth, medial-to-lateral width,
nd calculated renal volume are provided in Table III. At a
edian interval between the before and after stenting imaging
tudies of 21months (IQR, 13-32months), ipsilateral kidney
idth, depth, and volume were significantly increased from
aseline. For the cohort as a whole, ipsilateral renal volume
ncreased by 6.9% from baseline (IQR, 7.2% to 29.9%
hange). By comparison, the contralateral, unstented kidneys
f patients undergoing unilateral stenting had a median renal
olume loss of 52.7% (IQR, –61.0% to –46.7% change). It is
oteworthy that the 25 patients who were deemed “nonre-
ponders” to RAS by their postoperative BP and renal func-
ion—clinical failures using traditional definitions—experi-
nced a 12% relative increase in ipsilateral renal volume after
AS.
A significant negative correlation was observed be-
ween preoperative renal volume and the relative change in
tented kidney volume postoperatively (r  0.42; P 
0055), indicating that smaller kidneys experienced the
reatest gains in renal volume after stenting. It should be
oted, though, that the median preoperative kidney pole-
o-pole length was 10.0 cm (IQR, 9.1-10.7 cm), and only
5% of kidneys in the cohort had a pole-to-pole length of
9.1 cm (Table III). Net changes in stented kidney volume
(RAS)
Post-RAS P
134 (120-157) .012
71 (62-80) .045
3 (2-4) .88
1.39 (1.10-1.80) .16
50 (37-60) .22
2.60 .99
le ranges), or as indicated, and compared with Wilcoxon matched-pairs test.
able III. Kidney morphometrics of the cohort (n  45
idneys) before and after renal artery stenting (RAS)
ariable
Pre-RAS Post-RAS
PaMedian (IQR) Median (IQR)
psilateral kidney
Length, cm 10.0 (9.1-10.7) 10.0 (9.1-10.6) .37
Width, cm 5.4 (4.9-5.9) 5.9 (5.2-6.3) .02
Depth, cm 5.0 (4.6-5.6) 5.3 (4.7-5.7) .02
Volume, cm3 133.8 (106.2-170.5) 146.8 (124.4-189.6) .02
QR, Interquartile range.
P values by Wilcoxon matched-pairs test.nting
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definitions provided in the Methods section. Stable kidney
volumes were documented in 23.7%, increased kidney vol-
umes in 50.0%, and the remaining 26.3% had a net decrease
in kidney volume of 5%, compared with baseline.
An important question is whether the changes in renal
mass induced by RAS translate into improved clinical out-
comes over the long-term. First, the relationship between
postoperative changes in kidney volume changes and late
survival was examined. Survival was not significantly differ-
ent between patients with decreased kidney volume vs
those who had stable or increased renal volume (log-rank
test, P .63; Fig 1). The relationship between longitudinal
changes in kidney volume and changes in renal function
during late follow-up was also examined. For this analysis,
clinical follow-up at a median of 63 months after stenting
(IQR, 33-98 months) was used. The relative change in
postoperative renal volume from before to after stenting
correlated significantly with longitudinal changes in eGFR
at late clinical follow-up (r  0.47; P  .003). This rela-
tionship is depicted in Fig 2. Patients with kidney volume
loss after stenting (Fig 2, A) had a significant decrease in
eGFR during the 71 months after stenting (P  .02),
whereas patients with stable or increased kidney volume
(Fig 2, B and C) had no significant change in eGFR at 53
and 86 months of follow-up (P  .63 and P  .38),
respectively. The relative change in eGFR from baseline was
significantly different among the three groups (P  .004)
and paralleled the changes in kidney volume.
A comparison of patients with stable or improved renal
function vs those who experienced deterioration in late
Fig 1. Kaplan-Meier plot depicts survival after renal artery stent-
ing (RAS) for patients with stable or increased renal volume after
RAS (solid line) vs patients with decreased renal volume after
stenting (dashed line). The ticks along the lines represent censored
cases. The number at risk is provided for each interval. The
standard error for the stable/improved renal volume and de-
creased renal volume groups was 10% at 80 and 22 months,
respectively. The difference in survival between the two groups was
not significant (log-rank test, P  .63).renal function (20% decline in eGFR from prestenting) adentified four variables that differed significantly between
he two groups (Table IV). Three of the four variables were
ncluded in a multivariate model to identify predictors of
table or improved renal function at late follow-up. Preop-
rative serum creatinine was not included in the model
ecause preoperative eGFR was included. Multivariate
ig 2. The relationship between longitudinal changes in kidney
olume and changes in estimated glomerular filtration rate (eGFR)
s shown over time. The decrease in eGFR from immediately
efore stenting (time 0 on the curve) to late follow-up is shown for
A) the 10 patients who experienced kidney volume loss, (B) the 9
atients with stable kidney volume, and (C) the 19 patients with
ncreased kidney volume. Values for eGFR at each interval repre-
ent medians with interquartile ranges. The relative changes in
GFR from baseline were significantly different among the three
roups (P  .004 by Kruskal-Wallis test).nalysis identified two independent predictors of stable or
u
s
i
i
f
i
h
t
b
c
c
c
f
n
c
a
i
c
s
t
d
s
a
s
s
t
v
or F
JOURNAL OF VASCULAR SURGERY
March 2012778 Modrall et alimproved long-term renal function: (1) age (odds ratio,
1.3; 95% confidence interval, 1.0-1.5; P  .016); and (2)
stable or improved kidney volume after RAS (odds ratio,
0.008; 95% confidence interval, 0.000-0.206; P  .004).
These data indicate that patients with stable or improved
kidney volume after RAS have a 1% chance of experienc-
ing a late deterioration in eGFR of 20% from baseline.
To help clinicians select patients for RAS, we compared
the cohort with stable or increased kidney volume after
stenting with the cohort with decreased kidney volume to
identify preoperative clinical or morphologic differences in
the groups. There were no significant differences between
the two cohorts in age, systolic or diastolic BP, number of
antihypertensive medications, clonidine use, eGFR, inci-
dence of bilateral RA stenosis or solitary kidneys, kidney
length, kidney width, or kidney depth.
DISCUSSION
The traditional indications for RAS in patients with
RAOD are control of renal function and salvage of renal
function. Although proponents of stenting have suggested
that stentingmay preserve renalmass, there are limited data to
support that contention. The current study provided evidence
to support this concept: a net increase in kidney volume of
6.9% was seen after RAS. Indeed, half of the patients experi-
enced a net increase in kidney volume of at5%over baseline,
and one-quarter had stable kidney volumes (5% change
from baseline) after stenting. By comparison, the contralat-
eral, unstented kidneys of patients undergoing unilateral RAS
Table IV. Comparison of clinical parameters for patients w
follow-up after renal artery stenting (RAS)
Pre-RAS variablea
Stable/impro
(n  28)
Age, years 70 (63-75)
Male sex 50.00
Race
White 67.90
African American 25.00
Other 7.1
Diabetes 50.00
Serum creatinine, mg/dL 1.2 (0.9-1.6)
eGFR, mL/min/1.73 m2 60 (45-60)
Decline in eGFR per week, % 0.0 (1.2 to
Pre-RAS dialysis 0
Solitary kidney 7.10
Bilateral stenting 21.40
Kidney volume
Pre-RAS ipsilateral cm3 152 (107-173
Relative change post-RAS, % 12.7 (0.8 to
Blood pressure
Systolic, mm Hg 152 (137-172
Diastolic, mm Hg 74 (66-91)
Blood pressure medications, No. 3.0 (2.0-4.0)
eGFR, Estimated glomerular filtration rate.
aCategoric data are presented as the percentage and were compared with 
(interquartile ranges) and were compared with the Mann-Whitney U test.had significant ongoing loss of kidney volume during follow- op.This findingprovides additional circumstantial evidence to
uggest that RAS preserves renal mass. Interestingly, the pos-
tive effect on kidney volumewas not necessarily concentrated
n those patients who experienced a favorable BP or renal
unction response to stenting. In fact, there was a 12% net
ncrease in kidney volume in the subset of patients whowould
ave been considered treatment failures by traditional defini-
ions.
It may be argued that preserving kidney mass is only
eneficial if it is associated with improved clinical out-
omes, such as improved long-term renal function. In the
urrent study, we confirmed an association between
hanges in postoperative kidney volume and late renal
unction. Specifically, patients with stable or increased kid-
ey volume had stable long-term renal function in89% of
ases, whereas the subset with decreased kidney volume
fter RAS commonly experienced progressive deterioration
n renal function. These data suggest that longitudinal
hanges in kidney volume induced by RAS will have a
ignificant bearing on future renal function.
The results of the current study appear to lend credence to
he purported potential of RAS to preserve renal mass. These
ata raise an important question regarding the end points that
hould be used to judge the success or failure of RAS. In
ddition to early changes in BP and renal function, our data
uggest that changes in kidney volume after RAS may be a
urrogate marker for late changes in renal function. As such,
hese data provide a rationale for using changes in kidney
olume after stenting as an additional early end point to assess
stable or improved vs worsened renal function at late
Renal function
P
Worsened
(n  10)
61 (58-67) .03
57.10 .73
.6
50.00
40.00
10.0
40.00 .72
1.6 (1.5-2.4) .01
45 (29-55) .04
0.0 (4.9 to 2.5) .28
0 .99
0 .99
10.00 .65
129 (104-167) .48
10.7 (21.8 to 5.3) .005
159 (126-174) .83
79 (68-87) .92
3.0 (3.0-4.3) .38
isher exact test, as appropriate. Continuous data are presented as mediansith
ved
0.0)
)
35.0)
)
2utcomes for RAS. Many interventionalists use pole-to-pole
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but the data in Table III show that kidney length was less
sensitive than kidney width, depth, or volume in detecting
changes in kidney size after RAS. These data question the
utility of using kidney length in patient selection and argue
instead for using kidney volume in assessingparenchymalmass
before and after stenting.
To our knowledge, the current study is one of only two
reports to focus primarily on kidney volume changes after
RAS. Davies et al11 reported a series of 592 RA interventions
in which one-third had a loss of renal volume after stenting.
Those patients with loss of parenchymal volume had a higher
rate of progression to dialysis andworse survival. The results of
the current study confirm and extend the results from the
Davies study. In the current study, patients with stable or
increased renal volume were the primary focus, rather than
those with decreased kidney volume after stenting. We found
that stabilization or increase in renalmass after stentingwas an
independent predictor of stable or improved renal function at
late follow-up.
The results of the current study are provocative, but
some limitations must be acknowledged. Themost obvious
limitation is the small sample size. Unfortunately, the clin-
ical vascular laboratories at our affiliated hospitals did not
report kidney size in all three dimensions during the study
period, which excluded many RAS patients from this study.
Additional validation of the findings of this study in a larger
cohort is warranted before these data can be incorporated
into clinical practice.
A second limitation is the applicability of kidney vol-
umes derived from CT angiography and MR angiography
when most patients do not undergo either assessment
before RAS. Future studies should be aimed at validating
these findings using duplex ultrasound imaging to measure
kidney volume. We recommend that clinical vascular labo-
ratories routinely measure kidney size in all three dimen-
sions so that renal volume can be monitored longitudinally.
Finally, duplex-derived renal resistive indices were not
available for most patients,12 so we were unable to deter-
mine the relative utility of renal volumes compared with
resistive indices as predictors of long-term changes in renal
function. Despite these relative limitations, the results of
the current study merit further investigation. Although it is
tempting to view the potential of RAS to stabilize or
increase renal volume as an additional justification for RAS,
further validation of these data is essential before clinical
practice patterns may be altered.
CONCLUSIONS
The data in this study lend credence to the belief that
RAS preserves renal mass in some patients. This benefit of
RAS even extends to those patients who would be consid-
ered treatment failures by traditional definitions. Patients Sith stable or increased renal volume after RAS had more
table renal function during long-term follow-up, whereas
atients with renal volume loss after stenting were prone to
eterioration of renal function.
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eDISCUSSION
Dr Astrid Moise (Cleveland, Ohio). I would like to thank the
Society and Dr Modrall and his group for the opportunity to
review this manuscript. In a retrospective study of 38 patients, the
authors sought to assess the longitudinal changes in renal volume
after renal artery stenting in an attempt to determine if renal mass
is preserved by stenting. As we know, a number of studies have
stated that renal artery stenting does not have any benefit, but we
do know that in a certain subset of patients it does. So I believe this
is a very important study to help further elucidate this.
I do have a few questions. I am curious that cross-sectional
imaging of magnetic resonance (MR) and computed tomography
(CT) was used. I am curious to know what your protocol is for
using MR and CT for patients in prestenting and poststenting
assessments. Do you believe MR and CT are more useful studies
than ultrasound imaging? They certainly are more expensive.
You listed that only three people were renal function respond-
ers. How important, then, is increased renal mass to improve renal
function, or do we not know? You do provide some convincing
data that those patients with stable or increased renal mass after
stenting don’t have significant decrement in glomerular filtration
rate (GFR). However, none of the patients pre or post were on
dialysis, according to your paper. So I am curious to know if you
think increased renal mass is significant in terms of clinical func-
tion. I am also curious to know if in-stent restenosis corresponded
to a decrease of renal mass. Did you get a chance to study that?
Lastly, I am curious to know if you looked at any differences
between diabetic and nondiabetic patients. In your paper you
stated that 47% of your patients, almost half, were diabetic. Were
there any differences in renal mass preservation between those two
groups?
Dr J. Gregory Modrall. Thank you very much for your
comments and your questions, and I will address them in order. It
is not our protocol to obtain routine CT angiograms or MR
angiograms before and after stenting. Our protocol involves mea-
surement of kidney parameters, but we haven’t historically looked
e
pt all three dimensions, and that, unfortunately, limited the size of
ur cohort tremendously. I have asked our vascular laboratories at
ur respective institutions to begin obtaining those in three dimen-
ions, but that is a relatively recent change in our protocol. In fact,
ost of the CT angiograms or MR angiograms were obtained to
nswer other questions in the care of these patients. Nonetheless,
e used the data that were available for this analysis. We believe
hat duplex-derived renal volume measurements would be equally
elpful and considerably less expensive.
Regarding the low rate of renal function responders, this result
s not surprising considering that the majority of the patients
nderwent renal artery stenting for hypertension control rather
han renal function response. Regardless of the indication for
tenting, there is a risk of late deterioration in renal function or
rogression to dialysis. We showed in this study that renal function
ay be stabilized in those patients who experience a stabilization
r improvement in renal volume after stenting.
In-stent stenoses were rare in this subgroup, and only two
atients developed this complication. Neither patient actually had
olume measurements before and after the in-stent stenoses were
dentified, so I cannot address the question of whether in-stent
tenosis impacts kidney volumes.
You bring up an excellent question about diabetes and the
ffect on renal failure. We did not examine this variable as an
ndependent predictor of change in renal volume or the end point
f the study. Certainly we will perform that analysis before the
anuscript is submitted.
Dr Linda Harris (Buffalo, NY). I enjoyed your paper. Did
ou look at the group of patients with worsening renal mass to see
f there were any anatomic features or comorbidities that might be
ssociated with this group or whether they might have had more
mbolization based on your postoperative imaging?
DrModrall.We searched for preoperative predictors of wors-
ning or decrease in renal volume, but were unable to identify any
redictors of decreased renal volume.
